晚期非小细胞肺癌的治疗：一线、维持及二线治疗——印度共识声明更新
Treatment of advanced nonsmall cell lung cancer: First line, maintenance and second line - Indian consensus statement update.
作者信息
Prabhash Kumar
机构信息
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India.
出版信息
South Asian J Cancer. 2019 Jan-Mar;8(1):1-17. doi: 10.4103/sajc.sajc_227_18.
Abstract
The management of advanced nonsmall cell lung cancer (NSCLC) patients is becoming increasingly complex with the identification of driver mutations/rearrangements and development/availability of appropriate targeted therapies. In 2017, an expert group of medical oncologists with expertise in treating lung cancer used data from published literature and experience to arrive at practical consensus recommendations on treatment of advanced NSCLC for use by the community oncologists. This was published subsequently in the Indian Journal of Cancer with a plan to be updated annually. The present document is an update to the 2017 document.
摘要
随着驱动基因突变/重排的发现以及合适的靶向治疗方法的研发和应用，晚期非小细胞肺癌（NSCLC）患者的管理变得日益复杂。2017年，一组在肺癌治疗方面具有专业知识的医学肿瘤学家专家小组利用已发表文献中的数据和经验，达成了关于晚期NSCLC治疗的实用共识建议，供社区肿瘤学家使用。该建议随后发表在《印度癌症杂志》上，并计划每年更新。本文件是对2017年文件的更新。
相似文献
1
Treatment of advanced nonsmall cell lung cancer: First line, maintenance and second line - Indian consensus statement update.晚期非小细胞肺癌的治疗：一线、维持及二线治疗——印度共识声明更新
South Asian J Cancer. 2019 Jan-Mar;8(1):1-17. doi: 10.4103/sajc.sajc_227_18.
2
Indian consensus statement for treatment of advanced non small cell lung cancer: First line, maintenance, and second line.印度晚期非小细胞肺癌治疗共识声明：一线、维持及二线治疗
Indian J Cancer. 2017 Jan-Mar;54(1):89-103. doi: 10.4103/ijc.IJC_136_17.
3
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC).癌症免疫治疗学会关于免疫治疗非小细胞肺癌（NSCLC）的共识声明。
J Immunother Cancer. 2018 Jul 17;6(1):75. doi: 10.1186/s40425-018-0382-2.
4
The Society of Thoracic Surgeons Expert Consensus on the Multidisciplinary Management and Resectability of Locally Advanced Non-small Cell Lung Cancer.胸外科医师协会关于局部晚期非小细胞肺癌多学科管理与可切除性的专家共识
Ann Thorac Surg. 2025 Jan;119(1):16-33. doi: 10.1016/j.athoracsur.2024.09.041. Epub 2024 Oct 17.
5
First-line therapy outcomes in patients with advanced stage nonsmall cell lung cancer treated at nongovernment tertiary care centrer in India: Experience from a real world practice.印度非政府三级医疗中心治疗的晚期非小细胞肺癌患者的一线治疗结果：来自真实世界实践的经验。
Indian J Cancer. 2017 Jan-Mar;54(1):182-186. doi: 10.4103/0019-509X.219594.
6
Advanced therapeutic options and importance of rebiopsy in epidermal growth factor receptor-tyrosine kinase inhibitor-progressed nonsmall cell lung carcinoma patients: An expert opinion.表皮生长因子受体-酪氨酸激酶抑制剂治疗进展的非小细胞肺癌患者的高级治疗选择及再次活检的重要性：专家意见
Indian J Cancer. 2017 Dec;54(Supplement):S31-S36. doi: 10.4103/ijc.IJC_520_17.
7
Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010.转移性非小细胞肺癌：病理和分子检测共识，一线、二线和三线治疗：1 次 ESMO 肺癌共识会议；2010 年卢加诺。
Ann Oncol. 2011 Jul;22(7):1507-1519. doi: 10.1093/annonc/mdr150. Epub 2011 May 2.
8
Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.已知存在突变或重排的晚期非小细胞肺癌的管理：最新证据与治疗方法
Ther Adv Respir Dis. 2016 Apr;10(2):113-29. doi: 10.1177/1753465815617871. Epub 2015 Nov 30.
9
Canadian consensus: inhibition of ALK-positive tumours in advanced non-small-cell lung cancer.加拿大共识：晚期非小细胞肺癌中ALK阳性肿瘤的抑制
Curr Oncol. 2016 Jun;23(3):196-200. doi: 10.3747/co.23.3120. Epub 2016 Jun 9.
10
Molecular testing for advanced non-small cell lung cancer in Malaysia: Consensus statement from the College of Pathologists, Academy of Medicine Malaysia, the Malaysian Thoracic Society, and the Malaysian Oncological Society.马来西亚晚期非小细胞肺癌的分子检测：马来西亚病理学院、医学科学院、马来西亚胸科学会和马来西亚肿瘤学会的共识声明。
Lung Cancer. 2019 Oct;136:65-73. doi: 10.1016/j.lungcan.2019.08.005. Epub 2019 Aug 5.
引用本文的文献
1
Navigating the complexity of BRAF mutations in non-small cell lung cancer: current insights and future prospects.应对非小细胞肺癌中BRAF突变的复杂性：当前见解与未来展望
Multidiscip Respir Med. 2024 Nov 15;19(1):992. doi: 10.5826/mrm.2024.992.
2
Treatment pattern and outcomes in T790M-mutated non-small cell lung cancer.T790M 突变型非小细胞肺癌的治疗模式与预后
Ecancermedicalscience. 2022 May 6;16:1385. doi: 10.3332/ecancer.2022.1385. eCollection 2022.
3
A brief report on the mutational landscape in non-small cell lung cancer of South Asian patients: Comparison at a US and an Indian Institution.南亚患者非小细胞肺癌突变图谱的简要报告：美国和印度机构的比较
Lung India. 2022 Jul-Aug;39(4):315-318. doi: 10.4103/lungindia.lungindia_428_21.
4
Sarcopenia and high NLR are associated with the development of hyperprogressive disease after second-line pembrolizumab in patients with non-small-cell lung cancer.肌肉减少症和高 NLR 与二线帕博利珠单抗治疗非小细胞肺癌患者后发生超进展性疾病有关。
Clin Exp Immunol. 2020 Dec;202(3):353-362. doi: 10.1111/cei.13505. Epub 2020 Aug 26.
5
Correlation of programmed death-ligand 1 expression with gene expression and clinicopathological parameters in Indian patients with non-small cell lung cancer.印度非小细胞肺癌患者程序性死亡配体1表达与基因表达及临床病理参数的相关性
Lung India. 2020 Mar-Apr;37(2):145-150. doi: 10.4103/lungindia.lungindia_488_19.
本文引用的文献
1
Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial.抗体偶联药物 ado-trastuzumab emtansine 治疗 HER2 突变型肺癌患者的疗效：一项 II 期篮子试验的结果。
J Clin Oncol. 2018 Aug 20;36(24):2532-2537. doi: 10.1200/JCO.2018.77.9777. Epub 2018 Jul 10.
2
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.奥希替尼治疗未经治疗的 EGFR 突变型晚期非小细胞肺癌。
N Engl J Med. 2018 Jan 11;378(2):113-125. doi: 10.1056/NEJMoa1713137. Epub 2017 Nov 18.
3
Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer.阿来替尼治疗 ALK 阳性非小细胞肺癌的关键性 II 期研究（NP28673 和 NP28761）的汇总全身疗效和安全性数据。
J Thorac Oncol. 2017 Oct;12(10):1552-1560. doi: 10.1016/j.jtho.2017.06.070. Epub 2017 Jul 6.
4
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.塞瑞替尼与化疗用于既往接受过化疗和克唑替尼治疗的间变性淋巴瘤激酶（ALK）重排的非小细胞肺癌患者（ASCEND-5）：一项随机、对照、开放标签、III 期临床试验。
Lancet Oncol. 2017 Jul;18(7):874-886. doi: 10.1016/S1470-2045(17)30339-X. Epub 2017 Jun 9.
5
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.阿来替尼对比克唑替尼用于未经治疗的 ALK 阳性非小细胞肺癌。
N Engl J Med. 2017 Aug 31;377(9):829-838. doi: 10.1056/NEJMoa1704795. Epub 2017 Jun 6.
6
Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement.克唑替尼胶囊治疗 ROS1 重排阳性的非小细胞肺癌的单臂、多中心 II 期临床研究
J Clin Oncol. 2017 Aug 10;35(23):2613-2618. doi: 10.1200/JCO.2016.71.3701. Epub 2017 May 18.
7
Targeting -Mutant Non-Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy.靶向 - 突变型非小细胞肺癌：从分子剖析到合理设计的治疗
Oncologist. 2017 Jul;22(7):786-796. doi: 10.1634/theoncologist.2016-0458. Epub 2017 May 9.
8
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.阿法替尼与吉非替尼治疗表皮生长因子受体（EGFR）突变阳性的晚期非小细胞肺癌患者：IIb期LUX-Lung 7试验的总生存数据
Ann Oncol. 2017 Feb 1;28(2):270-277. doi: 10.1093/annonc/mdw611.
9
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.一线塞瑞替尼与铂类化疗用于晚期ALK 重排非小细胞肺癌（ASCEND-4）：一项随机、开放标签、III 期研究。
Lancet. 2017 Mar 4;389(10072):917-929. doi: 10.1016/S0140-6736(17)30123-X. Epub 2017 Jan 24.
10
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.阿特珠单抗对比多西他赛用于既往治疗过的非小细胞肺癌患者（OAK）：一项3期、开放标签、多中心随机对照试验
Lancet. 2017 Jan 21;389(10066):255-265. doi: 10.1016/S0140-6736(16)32517-X. Epub 2016 Dec 13.
Zotero 插件